Blastomycosis, also known as blastomycosis, is a fungal infection caused by inhalation of Blastomyces dermatitidis spores commonly found in contaminated soil and water. Blastomycosis often affects the lungs but can spread to other parts of the body if left untreated. Treatment of the infection requires prescription antifungal drugs such as itraconazole and amphotericin B. The global blastomycosis treatment market comprises drugs that either are used to cure acute pulmonary and disseminated blastomycosis or to maintain remission. Mainstay of therapy involves the use of azoles such as itraconazole or fluconazole for at least 6-12 months.
The Blastomycosis Treatment Market is estimated to be valued at USD 202 Mn in 2024 and is expected to reach USD 321.6 Mn by 2031, growing at a compound annual growth rate (CAGR) of 6.9% from 2024 to 2031.
Key Takeaways
Key players operating in the blastomycosis treatment market are Janssen, Scynexis Inc, Novartis AG, Marck & Co., Inc., and Sun Pharmaceutical Industries Ltd.
The growing prevalence of fungal infections worldwide due to factors such as increased environmental pollution and shifting climatic conditions is fueling the demand for blastomycosis treatment drugs.
Leading pharmaceutical companies are investing heavily in research and development activities to develop novel antifungal drugs with improved efficacy and safety profiles to tap growth opportunities in emerging markets.
Market Key Trends
One of the key trends gaining traction in the blastomycosis treatment market is the rising number of clinical trials evaluating the efficacy and safety of newer antifungal drugs. For instance, in 2019, Scynexis Inc initiated a Phase 3 clinical trial to evaluate the efficacy and safety of its novel antifungal drug ibrexafungerp for the treatment of blastomycosis and other fungal infections. If successful, ibrexafungerp has the potential to capture a major market share in the next 5-7 years.
Porter’s Analysis
Threat of new entrants: Low barriers to entry due to low cost of manufacturing.
Bargaining power of buyers: High as buyers in the form of government bodies and healthcare providers are price sensitive.
Bargaining power of suppliers: Moderate as raw materials suppliers holds less bargaining power due to presence of substitutes.
Threat of new substitutes: Threat of antibiotic substitutes for blastomycosis treatment.
Competitive rivalry: High as major companies compete intensely on pricing and product differentiation.
Geographical Regions
North America holds the largest market share in terms of value due to large patient population and high healthcare expenditure in the US. Asia Pacific is anticipated to witness the fastest growth rate during forecast period owing to rising cases of fungal infections coupled with improving healthcare infrastructure in emerging countries like China and India.
What Are The Key Data Covered In This Blastomycosis Treatment Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Blastomycosis Treatment’s growth between 2024 and 2031.
:- Accurate calculation of the size of the Blastomycosis Treatment and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Blastomycosis Treatment Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Blastomycosis Treatment vendors
FAQ’s
Q.1 What are the main factors influencing the Blastomycosis Treatment?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Blastomycosis Treatment companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Blastomycosis Treatment’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it